Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
Nonalcoholic fatty liver disease (NAFLD) is a group of obesity-associated pathological changes characterized by abnormal accumulation of lipids in cells of the liver parenchyma. NAFLD and associated conditions, namely insulin resistance and type II diabetes mellitus (DM2), as well as the possible ri...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2017-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/9374 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729838372356096 |
|---|---|
| author | Apollinariya V. Bogolyubova Alexander Y. Mayorov Ekaterina E. Mishina Anton M. Schwartz Pavel V. Belousov |
| author_facet | Apollinariya V. Bogolyubova Alexander Y. Mayorov Ekaterina E. Mishina Anton M. Schwartz Pavel V. Belousov |
| author_sort | Apollinariya V. Bogolyubova |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease (NAFLD) is a group of obesity-associated pathological changes characterized by abnormal accumulation of lipids in cells of the liver parenchyma. NAFLD and associated conditions, namely insulin resistance and type II diabetes mellitus (DM2), as well as the possible risks of developing fibrosis and cirrhosis with a potential outcome in hepatocellular carcinoma, represent the primary health problems in developed countries, gradually replacing the importance of similar pathologies caused by the regular use of hepatotoxic doses of alcoholic beverages. Recent fundamental and clinical studies demonstrated the important role of the farnesoid receptor (FXR, NR1H4) in the regulation of the metabolism of glucose, lipids and bile acids. This review focuses on the molecular aspects of the pathogenesis of NAFLD, the role of FXR (NR1H4) in the biology of this disease, and the prospects for using different FXR (NR1H4) modulators for therapy of NAFLD and associated conditions such as metabolic syndrome and DM2, as well as a number of other FXR (NR1H4) – mediated diseases. |
| format | Article |
| id | doaj-art-d30df532fce74d6d8dfcbb518f2a4ae4 |
| institution | DOAJ |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2017-12-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-d30df532fce74d6d8dfcbb518f2a4ae42025-08-20T03:09:04ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782017-12-0120644945310.14341/DM93748409Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromesApollinariya V. Bogolyubova0Alexander Y. Mayorov1Ekaterina E. Mishina2Anton M. Schwartz3Pavel V. Belousov4<p>Engelhardt Institute of Molecular Biology</p><p>Endocrinology Research Centre</p><p>Endocrinology Research Centre</p><p>Engelhardt Institute of Molecular Biology</p><p>Engelhardt Institute of Molecular Biology</p>Nonalcoholic fatty liver disease (NAFLD) is a group of obesity-associated pathological changes characterized by abnormal accumulation of lipids in cells of the liver parenchyma. NAFLD and associated conditions, namely insulin resistance and type II diabetes mellitus (DM2), as well as the possible risks of developing fibrosis and cirrhosis with a potential outcome in hepatocellular carcinoma, represent the primary health problems in developed countries, gradually replacing the importance of similar pathologies caused by the regular use of hepatotoxic doses of alcoholic beverages. Recent fundamental and clinical studies demonstrated the important role of the farnesoid receptor (FXR, NR1H4) in the regulation of the metabolism of glucose, lipids and bile acids. This review focuses on the molecular aspects of the pathogenesis of NAFLD, the role of FXR (NR1H4) in the biology of this disease, and the prospects for using different FXR (NR1H4) modulators for therapy of NAFLD and associated conditions such as metabolic syndrome and DM2, as well as a number of other FXR (NR1H4) – mediated diseases.https://www.dia-endojournals.ru/jour/article/view/9374nonalcoholic fatty liver diseasenonalcoholic steatohepatitisfarnesoid x |
| spellingShingle | Apollinariya V. Bogolyubova Alexander Y. Mayorov Ekaterina E. Mishina Anton M. Schwartz Pavel V. Belousov Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes Сахарный диабет nonalcoholic fatty liver disease nonalcoholic steatohepatitis farnesoid x |
| title | Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes |
| title_full | Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes |
| title_fullStr | Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes |
| title_full_unstemmed | Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes |
| title_short | Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes |
| title_sort | farnesoid x receptor fxr as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes |
| topic | nonalcoholic fatty liver disease nonalcoholic steatohepatitis farnesoid x |
| url | https://www.dia-endojournals.ru/jour/article/view/9374 |
| work_keys_str_mv | AT apollinariyavbogolyubova farnesoidxreceptorfxrasapotentialtherapeutictargetinnonalcoholicfattyliverdiseaseandassociatedsyndromes AT alexanderymayorov farnesoidxreceptorfxrasapotentialtherapeutictargetinnonalcoholicfattyliverdiseaseandassociatedsyndromes AT ekaterinaemishina farnesoidxreceptorfxrasapotentialtherapeutictargetinnonalcoholicfattyliverdiseaseandassociatedsyndromes AT antonmschwartz farnesoidxreceptorfxrasapotentialtherapeutictargetinnonalcoholicfattyliverdiseaseandassociatedsyndromes AT pavelvbelousov farnesoidxreceptorfxrasapotentialtherapeutictargetinnonalcoholicfattyliverdiseaseandassociatedsyndromes |